Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03999749 |
| Title | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | NYU Langone Health |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| The Angeles Clinic | Los Angeles | California | 90025 | United States | Details | |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| NYU Langone Health | New York | New York | 10016 | United States | Details |